3Widmark JM. Imaging-related medication: a class overview. Proc (Bayl Univ Med Cent) ,2007,20:408-417.
4Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis : risk factor and incidence estimation. Radiology,2007,243 : 148-157.
5kuo PH, Kanal E, Abu,Aifa AK, et al. Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. Radiology,2007, 242 : 647 -649.
6Carr DH. Paramagnetic contrast media for magnetic resonance imaging of the mediastinum and lungs. J Thorac Imaging, 1985,1(1):74-78.
7Huang S, Liu C, Dai G, et al. Manipulation of tissue contrast using contrast agents for enhanced MR microscopy in ex vivo mouse brain. Neuroimage, 2009,46(3) : 589-599.
8Demartini WB, Eby PR, Peacock S, et al. Utility of targeted sonography for breast lesions that were suspicious on MRI. AJR Am J Roentgenol, 2009,192(4) :1128-1134.
9Tamada T, Ito K, Sone T, et al. Dynamic contrast-enhanced magnetic resonance imaging of abdominal solid organ and major vessel: comparison of enhancement effect between Gd-EOBDTPA and Gd-DTPA. J Magn Reson Imaging, 2009,29 (3) : 636-640.
10Gallez B, Baudelet C, Geurts M. Regional distribution of manganese found in the brain after injection of a single dose of manganese based contrast agents. Magn Reson Imaging, 1998, 16(10) :1211-1215.
